Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Xphozah Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Tabs—14, 60
Manufacturer
Generic Availability
NO
Mechanism of Action
Tenapanor is a locally acting inhibitor that targets the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the epithelium of the small intestine and colon. The inhibition of NHE3 leads to decreased sodium and phosphate absorption by reducing phosphate permeability through the paracellular pathway.
Xphozah Indications
Indications
As add-on therapy, to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Xphozah Dosage and Administration
Adult
Give prior to the first and last meals of the day. 30mg twice daily (in the AM and PM).
Children
Not established.
Xphozah Contraindications
Contraindications
Patients <6yrs of age. Known or suspected mechanical GI obstruction.
Xphozah Boxed Warnings
Not Applicable
Xphozah Warnings/Precautions
Warnings/Precautions
Monitor serum phosphorus; adjust dose as needed to manage GI tolerability. Discontinue if severe diarrhea occurs. Pregnancy. Nursing mothers.
Xphozah Pharmacokinetics
Absorption
Area under the curve (AUC), maximum concentration (Cmax): not determined.
Distribution
Plasma protein bound: ~99%.
Elimination
Fecal (~70%), renal (~9%).
Xphozah Interactions
Interactions
Antagonizes OATP2B1 substrates (eg, enalapril): monitor and adjust dose as needed. Separate by at least 3hrs with sodium polystyrene sulfonate.
Xphozah Adverse Reactions
Adverse Reactions
Diarrhea.
Xphozah Clinical Trials
See Literature
Xphozah Note
Not Applicable
Xphozah Patient Counseling
See Literature
